Article

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish model

2023-11-15

Abstract excerpt

Dravet syndrome (DS) is a severe genetic epilepsy primarily caused by de novo mutations in a voltage-activated sodium channel gene (SCN1A). Patients face life-threatening seizures that are largely resistant to available anti-seizure medications (ASM). Preclinical DS animal models are a valuable tool to identify candidate ASMs for these patients. Among these, scn1lab mutant zebrafish exhibiting spontaneous seizur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 36747029-d8e2-5731-aff3-b5cd21e121cb
DOI: 10.1101/2023.11.11.566723

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelDOI 10.1101/2023.11.11.566723Read

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read

Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafishSemantic proximity Read

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluramineSemantic proximity Read

Clemizole and Trazodone are Effective Antiseizure Treatments in a Zebrafish Model of STXBP1 DisorderSemantic proximity Read

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.Semantic proximity Read

Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish ModelSemantic proximity Read

Phenotype-based screening of synthetic cannabinoids in a Dravet Syndrome zebrafish modelSemantic proximity Read

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read

Development of an Antiseizure Drug Screening Platform for Dravet Syndrome at the NINDS contract site for the Epilepsy Therapy Screening ProgramSemantic proximity Read

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.Semantic proximity Read

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndromeSemantic proximity Read